Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average (2021 - 2025)

InMed Pharmaceuticals' Equity Average history spans 5 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Equity Average rose 45.28% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, up 45.28%, while the annual FY2025 figure was $11.3 million, 6.31% up from the prior year.
  • Equity Average reached $10.6 million in Q4 2025 per INM's latest filing, down from $12.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.7 million in Q4 2021 to a low of $1.3 million in Q3 2023.
  • Average Equity Average over 5 years is $9.8 million, with a median of $10.2 million recorded in 2025.
  • Peak YoY movement for Equity Average: tumbled 87.5% in 2023, then surged 600.8% in 2024.
  • A 5-year view of Equity Average shows it stood at $14.7 million in 2021, then dropped by 13.77% to $12.7 million in 2022, then plummeted by 87.4% to $1.6 million in 2023, then surged by 356.39% to $7.3 million in 2024, then skyrocketed by 45.28% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Equity Average are $10.6 million (Q4 2025), $12.5 million (Q3 2025), and $10.2 million (Q2 2025).